TGFB1 and neoplasm: YM101 is a bispecific antibody that blocks TGF‐β and murine PD‐L1, exhibiting potent antitumor activity in non‐inflamed cancers, like CT26 and B16 tumor models.[28] The antitumor activity of the combination of ALO (50 mg kg−1) and YM101 (10 mg kg−1) was investigated in subcutaneous tumor mouse models in vivo (Figure 8D).